Leerink Partnrs Estimates Pfizer’s Q3 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Leerink Partnrs lifted their Q3 2025 earnings per share (EPS) estimates for shares of Pfizer in a report issued on Wednesday, December 18th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $1.11 per share for the quarter, up from their previous estimate of $1.05. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer’s Q4 2025 earnings at $0.66 EPS, FY2026 earnings at $3.10 EPS, FY2027 earnings at $3.03 EPS and FY2028 earnings at $2.67 EPS.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.17) EPS.

Other analysts have also issued reports about the stock. Citigroup assumed coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.14.

Pfizer Trading Down 0.5 %

Shares of Pfizer stock opened at $25.77 on Friday. Pfizer has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a market capitalization of $146.04 billion, a PE ratio of 34.82, a price-to-earnings-growth ratio of 0.63 and a beta of 0.65. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s fifty day moving average price is $26.88 and its two-hundred day moving average price is $28.20.

Institutional Trading of Pfizer

A number of institutional investors have recently modified their holdings of the company. Gladius Capital Management LP boosted its position in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares during the last quarter. Quarry LP acquired a new position in shares of Pfizer during the 2nd quarter worth about $31,000. Financial Connections Group Inc. acquired a new position in Pfizer during the second quarter valued at approximately $34,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Pfizer during the 3rd quarter worth approximately $35,000. Finally, Joseph Group Capital Management grew its stake in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by insiders.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.67%. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 232.43%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.